Clinical trials: Patients With Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive, or ROS1-positive non-small cell lung cancer (NSCLC)
- Trial name
- NCT04641754
- Testing
- WX-0593 Tablets
- Where
- 41 sites in China
- Volunteers
- 176 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial
The purposes of this study are to determine: 1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2.
- Trial name
- NCT00061451
- Testing
- Pemetrexed, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Resectable Non-small Cell Lung Cancer
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage…
- Trial name
- NENI (NCT06169956)
- Testing
- Neoadjuvant nivolumab in combination with platinum-based chemotherapy
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Non-Squamous Non-Small Cell Lung Cancer
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with…
- Trial name
- NCT01366131
- Testing
- MEGF0444A, bevacizumab, carboplatin
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Non-Small-Cell Lung Cancer
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable…
- Trial name
- NCT04316364
- Testing
- SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic
- Where
- 7 sites in China
- Volunteers
- 537 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced lung cancer.
- Trial name
- NCT02906852
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Inivata
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics
Non-Small Cell Lung Cancer Metastatic
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following…
- Trial name
- NCT03732274
- Testing
- TEW-7197
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MedPacto, Inc.
Non-small Cell Lung Cancer
Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC
This is a Phase 1, open-label study of SH-1028 with dose escalation and dose expansion cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an…
- Trial name
- NCT03603262
- Testing
- SH-1028
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Advanced Nonhaematologic Malignancies
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum…
- Trial name
- NCT03780517
- Testing
- BOS172738
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 117 people
- Sponsor
- Boston Pharmaceuticals
Metastatic Non-small Cell Lung Cancer
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the…
- Trial name
- NCT03300115
- Testing
- AC0010
- Where
- 25 sites in China
- Volunteers
- 222 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Non-Small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00391274
- Testing
- pemetrexed, docetaxel
- Where
- 7 sites in China
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer
AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSCLC patients who received at least one…
- Trial name
- NCT03457220
- Where
- 7 sites in Taiwan
- Volunteers
- 423 people
- Sponsor
- AstraZeneca
Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of…
- Trial name
- NCT06525350
- Testing
- Glumetinib tablets, HB1801 (docetaxel, albumin-bound）, Docetaxel
- Volunteers
- 256 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC)…
- Trial name
- NCT01531790
- Testing
- Carboplatin, Pemetrexed, Endostar
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally…
- Trial name
- OAK (NCT02008227)
- Testing
- Atezolizumab, Docetaxel
- Where
- 208 sites in United States, Argentina and 29 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Nsclc
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.
- Trial name
- NCT03990077
- Testing
- HL-085, Docetaxel
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Non-small Cell Lung Cancer Metastatic
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib
- Trial name
- NCT04923945
- Testing
- Savolitinib
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Hutchison Medipharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.